Current Contracts

Program Solicitation PHS 2022-1

SOLICITATION TO BE ANNOUNCED IN THE NEAR FUTURE

Receipt Date: TBD

Applicants must use the Contract Proposal Submission (eCPS) website to submit their proposal. No other method of proposal submission is permitted. Instructions for electronic submission are provided in the solicitation. Actual contract topic numbers will be available in the solicitation.

The PHS 2022-1 Solicitaton includes following 17 contract topics released by the National Cancer Institute:

THERAPEUTICS

• Development of Senotherapeutic Agents for Cancer Treatment
• Cancer Treatment Technologies for Low-Resource Settings
• Synthetic Biology Gene Circuits for Cancer Therapy

MEDICAL DEVICES

• Developing Unbiased Medical Technologies to Reduce Disparities in Cancer Outcomes
• Ultra-Fast Dose Rate (FLASH) Radiation Detectors and Safety Systems
• Devices to Treat Secondary Lymphedema Following Cancer Treatment

CLINICAL DIAGNOSTICS & MOLECULAR ANALYSIS

• New Technologies to Analyze Extra-Chromosomal DNA in Cancer
• 3D Spatial Omics for Molecular and Cellular Tumor Atlas Construction
• Understanding Cancer Tumor Genomic Results: Technology Applications for Community Providers
• Advanced Sample Processing Platforms for Downstream Single-Cell Multi-Omic Analysis
• Cancer Prevention and Diagnosis Technologies for Low-Resource Settings
• At-Home Screening for Hepatitis C Virus
• Quantitative Biomarkers as Medical Device Development Tools for Cancer

INFORMATION TECHNOLOGY & BIOINFORMATICS

• Development of Computer-Aided Diagnosis Tools for Upper and Lower Gastrointestinal Tract Cancer Prevention
• Evaluation Datasets as Medical Device Development Tools for Testing Cancer Technologies

MANUFACTURING TECHNOLOGIES

• Advanced Manufacturing to Speed Availability of Emerging Autologous Cell-based Therapies

Please see the Board of Scientific Advisers meeting presentation for more information on the proposed topics. The actual solicitation will become available in the near future. 

For contract inquiries, contact: